Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: IndiaFázis nélkül

This is a Multicentre International Study Evaluating CT-based IGABT With / Without Either TRUS During BT/Pre BT MR as Per IBS-GECESTRO-ABS Recommendations for Target contouring-as an Alternative to MRIGABT for Cervical Cancer From Implementation Perspectives Under EMBRACE-III:TRIPLET IMPACT Study.

A legfontosabb adatok

Ki végzi
Homi Bhabha Cancer Hospital & Research Centre
Hol
Visakhapatnam (India)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
1200 fő, tervezett
Kezdés
2025. nov.
Várható befejezés
2031. nov.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • CT IGABT
A regiszteradat frissítve
2025. november 25.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan nőket keres, akiknek lokálisan előrehaladott méhnyakrákjuk van, és akik sugárkezelést kapnak heti ciszplatin kemoterápiával, majd CT-vel tervezett brachyterápiát.

Életkor
18 éves vagy idősebb
Nem
Csak nők
A betegség stádiuma
A méhnyak invazív laphámrákja, adenokarcinómája vagy adenosquamosus karcinómája, FIGO (2018) szerinti IB2–IVA stádium, a betegség teljes megszüntetését célzó kezeléssel.
Korábbi kezelés
Nem volt korábban kismedencei vagy hasi sugárkezelése, nem volt teljes vagy részleges méheltávolítása, és a fő kezelés előtt nem kapott daganatellenes kezelést.

A részvétel fő kizáró okai

  • Más jelenlegi vagy korábbi rosszindulatú daganat, kivéve a méhnyak in situ karcinómáját
  • Az ágyéki nyirokcsomók áttétei, amelyek radikális sugárkezeléssel nem kezelhetők, vagy a para-aortikus áttét a vesereerek felett
  • Nem kaphat ciszplatin kemoterápiát (kreatinin-clearance 50mg/ml/min alatt)
  • Aktív fertőzés vagy súlyos betegség, amely kizárja a radikális kemoradioterápiát
  • Terhes, szoptat, vagy gyermeket vállalhat megfelelő fogamzásgátlás nélkül

A regiszter feltételei, szó szerint

Mind a 5 feltétel megnézéseKevesebb

Ki vehet részt

  • Cancer of the uterine cervix considered suitable for curative treatment with definitive chemo radiotherapy including brachytherapy
  • Biopsy showing invasive squamous-cell carcinoma or adenocarcinoma or adeno - squamous cell carcinoma of the uterine cervix
  • FIGO (2018) stage IB2 to IVA
  • Willingness to participate by signing informed consent form

Ki nem vehet részt

  • Other previous or current primary malignancies except carcinoma in situ of the cervix; Metastatic Inguinal Nodes not amenable to radical radiation therapy; Metastatic disease in para-aortic region beyond renal vessels; Not eligible for concurrent cisplatin chemotherapy (creatinine clearance < 50mg/ml/min); Previous pelvic or abdominal radiotherapy; Previous total or partial hysterectomy; Patients receiving BT alone; Patients receiving EBRT alone; Patients receiving any form of neoadjuvant anti-neoplastic therapy prior to definitive treatment or adjuvant therapy; Active infection or severe medical condition which precludes radical chemoradiotherapy; Pregnant or lactating or childbearing potential without adequate contraception

Helyszínek itt: India

  • Homi Bhabha Cancer Hopsital & Research CentreVisakhapatnam, IndiaContact: Dr Umesh Mahanshetty, MD, DNBToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

Title: Integration of Multi-modality Imaging Protocols with Emphasis on CT in Image-Guided Adaptive Brachytherapy (IGABT) for Cervical Cancer - EMBRACE III-TRIPLET : IMPACT Study Locally advanced cervical cancer (LACC) remains a major health challenge, particularly in low- and middle-income countries (LMICs), which account for the majority of global cases. The standard curative treatment involves a combination of external beam radiotherapy (EBRT) with concurrent chemotherapy, followed by brachytherapy (BT). Brachytherapy plays a crucial role in achieving high local control by delivering radiation directly to the tumour through internally placed radioactive sources.

A teljes eredeti leírásKevesebb

Historically, BT dose prescription was based on two-dimensional (2D) X-ray images and defined anatomical "points," achieving 5-year local control rates of 60-70%. Over the last decade, magnetic resonance imaging (MRI)-based image-guided adaptive brachytherapy (MR-IGABT) has transformed practice by enabling three-dimensional (3D) target-based dose prescription and adaptation to tumour regression. The landmark EMBRACE I study, involving over 1300 patients, demonstrated over 90% 5-year local control rates with MR-IGABT, establishing it as the international gold standard endorsed by NCG, ICRU, NCCN, and ESGO-ESTRO guidelines.

However, MRI-based planning for IGABT remains logistically and financially challenging for many centres, especially in LMICs. CT and transrectal ultrasound (TRUS) have emerged as feasible alternatives, offering broader accessibility. Despite encouraging outcomes from smaller institutional studies, the lack of standardized and validated target delineation concepts for CT-IGABT has led to significant variability in clinical implementation. Recognizing this, the Indian Brachytherapy Society (IBS), American Brachytherapy Society (ABS), and GEC-ESTRO jointly published consensus recommendations in 2020 to standardize CT-IGABT practices across diverse clinical environments.

At Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, our prior work (RetroLACER Study) demonstrated that CT-based IGABT can achieve outcomes comparable to MR-IGABT, highlighting its feasibility and potential for wider adoption. Building on this foundation, the EMBRACE III-IMPACT Study seeks to evaluate whether CT-IGABT can be systematically and uniformly implemented in a multi-centre setting and to benchmark clinical outcomes against the standards set by MR-IGABT.

Study Design:

This is a multicentre, prospective, observational study planned to include approximately 1200 participants with locally advanced cervical cancer. All participants will receive standard-of-care treatment, including EBRT, concurrent weekly cisplatin chemotherapy, and brachytherapy with image-guided planning.

Objectives:

To assess the feasibility of implementing standardized CT-IGABT protocols across diverse clinical environments.

To evaluate local control, disease-free survival, and treatment-related toxicity outcomes for CT-IGABT.

To compare and benchmark CT-IGABT outcomes with established MR-IGABT benchmarks from prior international studies.

Participant Involvement:

Participants will undergo standard diagnostic imaging, EBRT with weekly cisplatin, and brachytherapy using CT-based planning. Imaging and treatment data will be collected, anonymized, and submitted to a central database for review. Regular follow-up visits will monitor tumour control and treatment-related side effects.

Benefits:

Participants receive internationally standardized, quality-assured treatment protocols. Centres gain access to expert review and QA support from international collaborators, potentially improving treatment quality and outcomes.

The study supports global efforts to establish CT-IGABT as a cost-effective, accessible alternative to MRI-based IGABT, expanding equitable cancer care access.

Risks:

The study is observational and involves standard treatment; therefore, risks and costs are comparable to routine cervical cancer care.

Confidentiality and Ethics:

All data will be anonymized and handled in compliance with ethical and regulatory standards. Participant confidentiality will be strictly maintained. Written informed consent will be obtained before study participation.

Significance:

By validating standardised CT-based protocols and establishing outcome benchmarks, the study aims to facilitate widespread adoption of IGABT in resource-limited settings, ultimately improving treatment accessibility and survival outcomes.

A vizsgálat csoportja

  • Cohort A - Advanced CT Environment, Cohort B - Basic CT Environment

    COHORT A: Pre Brachytherapy MR to assess the regression of primary tumour after EBRT +/- CT, defining target and pre-planning of BT implantation followed by CT Imaging with BT applicator in place. Alternatively, if Pre-BT MR is not feasible, use of TRUS imaging information during BT application to define the target on CT Imaging with BT applicator in situ COHORT B: CT Imaging with BT Applicator in place-based treatment planning for each BT application.

    Kezelés: CT IGABT

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Integration of Multi-modality Imaging Protocols With emphAsis on CT in Image Guided Adaptive Brachytherapy (IGABT) for Cervical Cancer - EMBRACE III-IMPACT STUDY
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2025. november 25.